Nexus
  • Home
  • Our Company
    • About Us
    • Focus and Responsibility
    • Team and Culture
  • Products
  • Careers
  • News
    • Nexus Pharmaceuticals’ Manufacturing Facility
  • Contact Us
Select Page
Nexus Pharmaceuticals Announces Great Places to Work® Certification

Nexus Pharmaceuticals Announces Great Places to Work® Certification

by Julie Stewart | Nov 19, 2019 | News

Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute. Ninety percent of Nexus employees say the company is a great place to work. The company is proud to employ individuals with a strong work...
Nexus Pharmaceuticals Ranks #574 in Inc. 5000 Fastest-Growing Private Companies in America

Nexus Pharmaceuticals Ranks #574 in Inc. 5000 Fastest-Growing Private Companies in America

by Julie Stewart | Aug 15, 2019 | News

Nexus Pharmaceuticals is pleased to announce the company has ranked #574 in Inc. 5000’s Fastest-Growing Private Companies in America in 2019. Since inception in 2003, and the launch of its first injectable drug in 2017, Nexus Pharmaceuticals has experienced...
Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin

Nexus Pharmaceuticals to Build Industry-Leading Sterile Injectable Manufacturing Facility in Pleasant Prairie, Wisconsin

by Patrick Weeks | Jul 11, 2019 | News

● The multi-stage, multi-year project is expected to be completed in ten years, with an estimated investment of $250m. ● The only project of its kind in sterile generic injectables in the last 30 years. ● The facility will be located in Pleasant Prairie, Wisconsin,...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

by Patrick Weeks | Feb 21, 2019 | News

Lincolnshire, Ill., February 21, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. “The launch further expands our generic injectable portfolio...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Announces FDA Approval of Dicyclomine HCl Injection, USP

by Patrick Weeks | Feb 14, 2019 | News

Lincolnshire, Ill., February 14, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in 20mg/2mL vial, the generic equivalent to Bentyl®. Dicyclomine HCl, USP,...
Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Nexus Pharmaceuticals Announces FDA Approval of Busulfan Injection

by Patrick Weeks | Jan 16, 2019 | News

Lincolnshire, Ill., January 16, 2019 — Nexus Pharmaceuticals Inc. announced today the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL). “The FDA approval of...
« Older Entries
VERIFIED Seal